EntityQ4747983· pop 8· linked from 556 articles

Amosulalol

Amosulalol (INN) is an antihypertensive drug. It has much higher affinity for α1-adrenergic receptors than for β-adrenergic receptors. It is not approved for use in the United States. ==Synthesis== upright=2|class=skin-invert-image

Research

45 papers

Effects of (+)- and (-)-amosulalol on the rat isolated right ventricle.Journal of cardiovascular pharmacology · 1987
Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxy derivative (YM-11133).The Journal of pharmacology and experimental therapeutics · 1986
The effects of amosulalol, a novel combined alpha- and beta-adrenoreceptor antagonist, on the rat isolated right ventricle and aorta.Journal of autonomic pharmacology · 1985
Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses.Clinical pharmacology and therapeutics · 1984
Effect of topical amosulalol on tissue circulation in the optic nerve head.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 1999

via PubMed

Article

2 sections

Contents

Synthesis
References

Guaiacol (1) reacts with ethylene oxide to give 2-(2-methoxyphenoxy)ethanol (2). Halogenation with thionyl chloride converts the alcohol group to a chloride, (3), which is used to alkylate benzylamine (4) to give the secondary amine (5). This forms a tertiary amine (7) when combined with 5-bromoacetyl-2-methylbenzenesulfonamide (6). The reduction of the carbonyl group with sodium borohydride produces (8) and catalytic hydrogenation removes the benzyl group, yielding amosulalol.